<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Lu D</submitter><funding>Intramural NIH HHS</funding><funding>National Cancer Institute</funding><pagination>159089</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8864892</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>1867(2)</volume><pubmed_abstract>In addition to maintaining bile acid, cholesterol and glucose homeostasis, farnesoid X receptor (FXR) also regulates fatty acid β-oxidation (FAO). To explore the different roles of hepatic and intestinal FXR in liver FAO, FAO-associated metabolites, including acylcarnitines and fatty acids, and FXR target gene mRNAs were profiled using an integrated metabolomic and transcriptomic analysis in control (Fxr&lt;sup>fl/fl&lt;/sup>), liver-specific Fxr-null (Fxr&lt;sup>ΔHep&lt;/sup>) and intestine-specific Fxr-null (Fxr&lt;sup>ΔIE&lt;/sup>) mice, treated either with the FXR agonist obeticholic acid (OCA) or vehicle (VEH). Activation of FXR by OCA treatment significantly increased fatty acyl-CoA hydrolysis (Acot1) and decreased FAO-associated mRNAs in Fxr&lt;sup>fl/fl&lt;/sup> mice, resulting in reduced levels of total acylcarnitines and relative accumulation of long/medium chain acylcarnitines and fatty acids in liver. Fxr&lt;sup>ΔHep&lt;/sup> mice responded to OCA treatment in a manner similar to Fxr&lt;sup>fl/fl&lt;/sup> mice while Fxr&lt;sup>ΔIE&lt;/sup&gt; mice responded differently, thus illustrating that intestinal FXR plays a critical role in the regulation of hepatic FAO. A significant negative-correlation between intestinal FXR-FGF15 and hepatic CREB-PGC1A pathways was observed after both VEH and OCA treatment, suggesting that OCA-induced activation of the intestinal FXR-FGF15 axis downregulates hepatic PGC1α signaling via inactivation of hepatic CREB, thus repressing FAO. This mechanism was confirmed in experiments based on human recombinant FGF19 treatment and intestinal Fgf15-null mice. This study revealed an important role for the intestinal FXR-FGF15 pathway in hepatic FAO repression.</pubmed_abstract><journal>Biochimica et biophysica acta. Molecular and cell biology of lipids</journal><pubmed_title>Intestinal farnesoid X receptor signaling controls hepatic fatty acid oxidation.</pubmed_title><pmcid>PMC8864892</pmcid><funding_grant_id>Z01 BC005562</funding_grant_id><pubmed_authors>Krausz KW</pubmed_authors><pubmed_authors>Lu D</pubmed_authors><pubmed_authors>Yan T</pubmed_authors><pubmed_authors>Feng C</pubmed_authors><pubmed_authors>Xu J</pubmed_authors><pubmed_authors>Xiao P</pubmed_authors><pubmed_authors>Liu Y</pubmed_authors><pubmed_authors>Wang Q</pubmed_authors><pubmed_authors>Luo Y</pubmed_authors><pubmed_authors>Xue L</pubmed_authors><pubmed_authors>Gonzalez FJ</pubmed_authors><pubmed_authors>Zhao J</pubmed_authors><pubmed_authors>Xie C</pubmed_authors></additional><is_claimable>false</is_claimable><name>Intestinal farnesoid X receptor signaling controls hepatic fatty acid oxidation.</name><description>In addition to maintaining bile acid, cholesterol and glucose homeostasis, farnesoid X receptor (FXR) also regulates fatty acid β-oxidation (FAO). To explore the different roles of hepatic and intestinal FXR in liver FAO, FAO-associated metabolites, including acylcarnitines and fatty acids, and FXR target gene mRNAs were profiled using an integrated metabolomic and transcriptomic analysis in control (Fxr&lt;sup>fl/fl&lt;/sup>), liver-specific Fxr-null (Fxr&lt;sup>ΔHep&lt;/sup>) and intestine-specific Fxr-null (Fxr&lt;sup>ΔIE&lt;/sup>) mice, treated either with the FXR agonist obeticholic acid (OCA) or vehicle (VEH). Activation of FXR by OCA treatment significantly increased fatty acyl-CoA hydrolysis (Acot1) and decreased FAO-associated mRNAs in Fxr&lt;sup>fl/fl&lt;/sup> mice, resulting in reduced levels of total acylcarnitines and relative accumulation of long/medium chain acylcarnitines and fatty acids in liver. Fxr&lt;sup>ΔHep&lt;/sup> mice responded to OCA treatment in a manner similar to Fxr&lt;sup>fl/fl&lt;/sup> mice while Fxr&lt;sup>ΔIE&lt;/sup&gt; mice responded differently, thus illustrating that intestinal FXR plays a critical role in the regulation of hepatic FAO. A significant negative-correlation between intestinal FXR-FGF15 and hepatic CREB-PGC1A pathways was observed after both VEH and OCA treatment, suggesting that OCA-induced activation of the intestinal FXR-FGF15 axis downregulates hepatic PGC1α signaling via inactivation of hepatic CREB, thus repressing FAO. This mechanism was confirmed in experiments based on human recombinant FGF19 treatment and intestinal Fgf15-null mice. This study revealed an important role for the intestinal FXR-FGF15 pathway in hepatic FAO repression.</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Feb</publication><modification>2025-04-19T17:58:46.769Z</modification><creation>2025-04-19T17:58:46.769Z</creation></dates><accession>S-EPMC8864892</accession><cross_references><pubmed>34856412</pubmed><doi>10.1016/j.bbalip.2021.159089</doi></cross_references></HashMap>